**Supplementary material:** Pirfenidone For Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of A NICE Single Technology Appraisal

|  |
| --- |
| **Supplementary Table 1: Pirfenidone vs placebo: differences by secondary outcomes** |
| **Outcome** | **Trials** | **Time point****(weeks)** | **Treatment group** | **Outcome by treatment group** | **Difference, *p*-value** |
| **Change in 6MWD from baseline, mean in metres** | ASCEND[10] | 52  | PFN (n=278) | -33.5 | 0.036 |
| PBO(n=277) | -60.2 |
| CAPACITY 1[11] | 72  | PFN (n=174) | -45.1 | <0.001 |
| PBO (n=174) | -79.6 |
| CAPACITY 2[11] | 72  | PFN (n=171) | -60.4 | 0.171 |
| PBO (n=173) | -76.8 |
| **SGRQ, Change from baseline to Week 72, mean ± SD** | CAPACITY 1[11] | 72  | PFN (n=166) | 7.2 ± 16.85 | 0.766a |
| PBO (n=169) | 7.3 ± 20.37 |
| CAPACTIY 2[11] | 72  | PFN (n=163) | 7.6 ± 18.89 | 0.495a |
| PBO (n=165) | 9.0 ± 18.86 |
| **UCSD SOBQ, Change in dyspnoea score from baseline, mean** | ASCEND [10]  | 52  | PFN (n=278) | 14 | NR |
| PBO (n=277) | 17.3 |
| CAPACITY 1[11] | 72  | PFN (N=171) | 11.9 | 0.604b |
| PBO(N=173) | 13.9 |
| CAPACITY 2[11] | 72  | PFN(N=174) | 12.1 | 0.509b |
| PBO(N=174) | 15.2 |
| **UCSD SOBQ, categorical outcome for worsening or death, n( %) c** | ASCEND[10] | 52  | PFN (n=278) | Worsening score ≥20 points or death: 81 (29.1) | 0.1577b |
| Worsening score <20 to 0 points: 124 (44.6) |
| No worsening (score change <0 points): 73 (26.3) |
| PBO (n=277) | Worsening score ≥20 points or death:100 (36.1) |
| Worsening score <20 to 0 points:115 (41.5) |
| No worsening (score change <0 points): 62 (22.4) |
| *aRank ANCOVA stratified by geographic region (USA and rest of world). Missing data due to a patient’s death were ranked as worse than any non-death and according to time until death**bRank ANCOVA (pirfenidone 2403 mg/day vs placebo)**c Missing data due to reasons other than death were imputed using the sum of squared differences (SSD) method and included in the ≥20 points category**Abbreviations: 6MWD, 6 minute walking distance; PBO, placebo; PFN, pirfenidone (2403mg/day); UCSD SOBQ, University of San Diego Shortness of Breath Questionnaire; SGRQ, St George’s Respiratory Questionnaire; NR: Not Reported* |